Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2008

01.10.2008 | Hepatic and Pancreatic Tumors

Surgical Management of Hepatocellular Adenoma: Take It or Leave It?

verfasst von: Sung W. Cho, MBBS, MSc, J. Wallis Marsh, MD, Jennifer Steel, PhD, Shane E. Holloway, MD, Jason T. Heckman, MD, Erin R. Ochoa, MD, David A. Geller, MD, T. Clark Gamblin, MD, MS

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular adenoma (HA) is a rare benign tumor of the liver. Surgical resection is generally indicated to reduce risks of hemorrhage and malignant transformation. We sought to evaluate clinical presentation, surgical management, and outcomes of patients with HA at our institution.

Methods

We performed a retrospective review of 41 patients who underwent surgical resection for HA between 1988 and 2007.

Results

Thirty-eight patients were women, and the median age at presentation was 36 years (range, 19–65 years). The most common clinical presentation was abdominal pain (70%) followed by incidental radiological finding (17%). Twenty-two patients had a history of oral contraceptive use. Median number of HA was one (range, 1–3). There were 32 open cases (3 trisectionectomy, 15 hemihepatectomy, 7 sectionectomy, 4 segmentectomy, and 3 wedge resection), and 9 laparoscopic cases (1 hemihepatectomy, 5 sectionectomy, 1 segmentectomy, and 2 wedge resection). The median estimated blood loss was 225 mL (range, 0–3400 mL). The median length of stay was 6 days (range, 1–15 days). Surgical morbidities included pleural effusion requiring percutaneous drainage (n = 2), pneumonia (n = 1), and wound infection (n = 1). There was no perioperative mortality. Twelve patients had hemorrhage from HA. Hepatocellular carcinoma was observed in two patients with HA. Median follow-up was 23 months (range, 1–194 months), at which time all patients were alive.

Conclusion

In view of 29% hemorrhagic and 5% malignant complication rates, we recommend surgical resection over observation if patient comorbidities and anatomic location of HA are favorable. A laparoscopic approach can be safely used in selected cases.
Literatur
1.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397–406PubMedCrossRef Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397–406PubMedCrossRef
2.
Zurück zum Zitat Koffron A, Geller D, Gamblin TC, et al. Laparoscopic liver surgery: shifting the management of liver tumors. Hepatology 2006;44:1694–700PubMedCrossRef Koffron A, Geller D, Gamblin TC, et al. Laparoscopic liver surgery: shifting the management of liver tumors. Hepatology 2006;44:1694–700PubMedCrossRef
3.
Zurück zum Zitat Descottes B, Glineur D, Lachachi F, et al. Laparoscopic liver resection of benign liver tumors. Surg Endosc 2003;17:23–30PubMedCrossRef Descottes B, Glineur D, Lachachi F, et al. Laparoscopic liver resection of benign liver tumors. Surg Endosc 2003;17:23–30PubMedCrossRef
4.
Zurück zum Zitat Paradis V, Laurent A, Flejou JF, et al. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997;26:891–5PubMedCrossRef Paradis V, Laurent A, Flejou JF, et al. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997;26:891–5PubMedCrossRef
5.
Zurück zum Zitat Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008;48:163–70PubMedCrossRef Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008;48:163–70PubMedCrossRef
6.
7.
Zurück zum Zitat Belghiti J, Pateron D, Panis Y, et al. Resection of presumed benign liver tumors. Br J Surg 1993;80:380–3PubMedCrossRef Belghiti J, Pateron D, Panis Y, et al. Resection of presumed benign liver tumors. Br J Surg 1993;80:380–3PubMedCrossRef
8.
Zurück zum Zitat Closset J, Veys I, Peny MO, et al. Retrospective analysis of 29 patients surgically treated for hepatocellular adenoma or focal nodular hyperplasia. Hepatogastroenterology 2000;47:1382–4PubMed Closset J, Veys I, Peny MO, et al. Retrospective analysis of 29 patients surgically treated for hepatocellular adenoma or focal nodular hyperplasia. Hepatogastroenterology 2000;47:1382–4PubMed
9.
Zurück zum Zitat De Carlis L, Pirotta V, Rondinara G, et al. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg 1997;3:160–5PubMedCrossRef De Carlis L, Pirotta V, Rondinara G, et al. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg 1997;3:160–5PubMedCrossRef
10.
Zurück zum Zitat Erdogan D, Busch ORC, van Delden OM, et al. Management of spontaneous hemorrhage and rupture of hepatocellular adenomas. a single center experience. Liver Int 2006;26:433–8PubMedCrossRef Erdogan D, Busch ORC, van Delden OM, et al. Management of spontaneous hemorrhage and rupture of hepatocellular adenomas. a single center experience. Liver Int 2006;26:433–8PubMedCrossRef
11.
Zurück zum Zitat Herman P, Pugliese V, Machado MAC, et al. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg 2000;24:372–6PubMedCrossRef Herman P, Pugliese V, Machado MAC, et al. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg 2000;24:372–6PubMedCrossRef
12.
Zurück zum Zitat Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995;19:13–8PubMedCrossRef Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995;19:13–8PubMedCrossRef
13.
Zurück zum Zitat Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979;242:644–8PubMedCrossRef Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979;242:644–8PubMedCrossRef
14.
Zurück zum Zitat Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001;21:877–92PubMed Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001;21:877–92PubMed
15.
Zurück zum Zitat Craig JR, Peters RL, Edmondson HA. Atlas of tumor pathology: tumors of the liver, intrahepatic bile ducts. Fasc 27, ser 2. Armed Forces Institute of Pathology: Washington, DC, 1989:19–41 Craig JR, Peters RL, Edmondson HA. Atlas of tumor pathology: tumors of the liver, intrahepatic bile ducts. Fasc 27, ser 2. Armed Forces Institute of Pathology: Washington, DC, 1989:19–41
16.
Zurück zum Zitat Ault G, Wren S, Ralls PW, et al. Selective management of hepatic adenomas. Am Surg 1996;62:825–9PubMed Ault G, Wren S, Ralls PW, et al. Selective management of hepatic adenomas. Am Surg 1996;62:825–9PubMed
17.
Zurück zum Zitat Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988;208:558–64PubMedCrossRef Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988;208:558–64PubMedCrossRef
18.
Zurück zum Zitat Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumors. Dig Surg 2002;19:109–13PubMedCrossRef Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumors. Dig Surg 2002;19:109–13PubMedCrossRef
19.
Zurück zum Zitat Tao LC. Oral contraceptive–associated liver cell adenoma and hepatocellular carcinoma. cytomorphology and mechanism of malignant transformation. Cancer 1991;68:341–7PubMedCrossRef Tao LC. Oral contraceptive–associated liver cell adenoma and hepatocellular carcinoma. cytomorphology and mechanism of malignant transformation. Cancer 1991;68:341–7PubMedCrossRef
20.
Zurück zum Zitat Anderson PH, Packer JT. Hepatic adenoma–observation after estrogen withdrawal. Arch Surg 1976;111:898–900 Anderson PH, Packer JT. Hepatic adenoma–observation after estrogen withdrawal. Arch Surg 1976;111:898–900
21.
Zurück zum Zitat Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001;33:234–6PubMedCrossRef Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001;33:234–6PubMedCrossRef
22.
Zurück zum Zitat Steinbrecher UP, Lisbona R, Huang SN, et al. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981;26:1045–50PubMedCrossRef Steinbrecher UP, Lisbona R, Huang SN, et al. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981;26:1045–50PubMedCrossRef
23.
Zurück zum Zitat Bühler H, Pirovino M, Akobiantz A, et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982;82:775–82PubMed Bühler H, Pirovino M, Akobiantz A, et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982;82:775–82PubMed
24.
Zurück zum Zitat Edmondson HA, Reynolds TB, Henderson B, et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977;86:180–2PubMed Edmondson HA, Reynolds TB, Henderson B, et al. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977;86:180–2PubMed
25.
Zurück zum Zitat Ramseur WL, Cooper MR. Asymptomatic liver cell adenomas. another case of resolution after discontinuation of oral contraceptive use. JAMA 1978;239:1647–8PubMedCrossRef Ramseur WL, Cooper MR. Asymptomatic liver cell adenomas. another case of resolution after discontinuation of oral contraceptive use. JAMA 1978;239:1647–8PubMedCrossRef
26.
Zurück zum Zitat Gordon SC, Reddy KR, Livingstone AS, et al. Resolution of a contraceptive-steroid–induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986;105:547–9PubMed Gordon SC, Reddy KR, Livingstone AS, et al. Resolution of a contraceptive-steroid–induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986;105:547–9PubMed
27.
Zurück zum Zitat Tesluk H, Lawrie J. Hepatocellular adenoma. its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981;105:296–9PubMed Tesluk H, Lawrie J. Hepatocellular adenoma. its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981;105:296–9PubMed
28.
Zurück zum Zitat Marks WH, Thompson N, Appleman H. Failure of hepatic adenomas (HCA) to regress after discontinuance of oral contraceptives. an association with focal nodular hyperplasia (FNH) and uterine leiomyoma. Ann Surg 1988;208:190–5PubMedCrossRef Marks WH, Thompson N, Appleman H. Failure of hepatic adenomas (HCA) to regress after discontinuance of oral contraceptives. an association with focal nodular hyperplasia (FNH) and uterine leiomyoma. Ann Surg 1988;208:190–5PubMedCrossRef
29.
Zurück zum Zitat Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994;129:712–7PubMed Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994;129:712–7PubMed
30.
Zurück zum Zitat Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46:740–8PubMedCrossRef Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46:740–8PubMedCrossRef
31.
Zurück zum Zitat Chen YW, Jeng YM, Yeh SH, et al. P53 Gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36(4 Pt 1):927–35PubMed Chen YW, Jeng YM, Yeh SH, et al. P53 Gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36(4 Pt 1):927–35PubMed
32.
Zurück zum Zitat Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 2001;3:68–73PubMed Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 2001;3:68–73PubMed
33.
Zurück zum Zitat Terkivatan T, de Wilt JH, de Man RA, et al. Management of hepatocellular adenoma during pregnancy. Liver 2000;20;186–7PubMedCrossRef Terkivatan T, de Wilt JH, de Man RA, et al. Management of hepatocellular adenoma during pregnancy. Liver 2000;20;186–7PubMedCrossRef
34.
Zurück zum Zitat Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004;187:181–91PubMedCrossRef Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004;187:181–91PubMedCrossRef
35.
Zurück zum Zitat Flowers BF, McBurney RP, Vera SR. Ruptured hepatic adenoma: a spectrum of presentation and treatment. Am Surg 1990;56:380–3PubMed Flowers BF, McBurney RP, Vera SR. Ruptured hepatic adenoma: a spectrum of presentation and treatment. Am Surg 1990;56:380–3PubMed
36.
Zurück zum Zitat Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001;136:1033–8PubMedCrossRef Terkivatan T, de Wilt JH, de Man RA, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001;136:1033–8PubMedCrossRef
37.
Zurück zum Zitat Atwell TD, Brandhagen DJ, Charboneau JW, et al. Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation. AJR Am J Roentgenol 2005;184:828–31PubMed Atwell TD, Brandhagen DJ, Charboneau JW, et al. Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation. AJR Am J Roentgenol 2005;184:828–31PubMed
38.
Zurück zum Zitat Ameriks JA, Thompson NW, Frey CF, et al. Hepatic cell adenomas, spontaneous liver rupture and oral contraceptives. Arch Surg 1975;110:548–57PubMed Ameriks JA, Thompson NW, Frey CF, et al. Hepatic cell adenomas, spontaneous liver rupture and oral contraceptives. Arch Surg 1975;110:548–57PubMed
39.
Zurück zum Zitat Ardito F, Tayar C, Laurent A, et al. Laparoscopic liver resection for benign disease. Arch Surg 2007;142:1188–93PubMedCrossRef Ardito F, Tayar C, Laurent A, et al. Laparoscopic liver resection for benign disease. Arch Surg 2007;142:1188–93PubMedCrossRef
40.
Zurück zum Zitat Arrive L, Flejou JF, Vilgrain V, et al. Hepatic adenoma: MR Findings in 51 pathologically proven lesions. Radiology 1994;193:507–12PubMed Arrive L, Flejou JF, Vilgrain V, et al. Hepatic adenoma: MR Findings in 51 pathologically proven lesions. Radiology 1994;193:507–12PubMed
41.
Zurück zum Zitat Charny CK, Janagin WR, Schwartz LH, et al. Management of 155 patients with benign liver tumors. Br J Surg 2001;88:808–13PubMedCrossRef Charny CK, Janagin WR, Schwartz LH, et al. Management of 155 patients with benign liver tumors. Br J Surg 2001;88:808–13PubMedCrossRef
42.
Zurück zum Zitat Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995;22:1674–81PubMedCrossRef Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995;22:1674–81PubMedCrossRef
43.
Zurück zum Zitat Chung KY, Mayo-Smith WW, Saini S, et al. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 1995;165:303–8PubMed Chung KY, Mayo-Smith WW, Saini S, et al. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 1995;165:303–8PubMed
44.
Zurück zum Zitat Descottes B, Lachachi F, Sodji M, et al. Early experience with laparoscopic approach for solid liver tumors: initial 16 cases. Ann Surg 2000;232:641–5PubMedCrossRef Descottes B, Lachachi F, Sodji M, et al. Early experience with laparoscopic approach for solid liver tumors: initial 16 cases. Ann Surg 2000;232:641–5PubMedCrossRef
45.
Zurück zum Zitat Gold JH, Guzman IJ, Rosai J. Benign tumors of the liver. Am J Clin Pathol 1978;70:6–17PubMed Gold JH, Guzman IJ, Rosai J. Benign tumors of the liver. Am J Clin Pathol 1978;70:6–17PubMed
46.
Zurück zum Zitat Golli M, van Nhieu JT, Mathieu D, et al. A hepatocellular adenoma: color Doppler US and pathologic correlations. Radiology 1994;190:741–4PubMed Golli M, van Nhieu JT, Mathieu D, et al. A hepatocellular adenoma: color Doppler US and pathologic correlations. Radiology 1994;190:741–4PubMed
47.
Zurück zum Zitat Hung CH, Changchien CS, Lu SN, et al. Sonographic features of hepatic adenomas with pathologic correlation. Abdom Imaging 2001;26;500–6PubMedCrossRef Hung CH, Changchien CS, Lu SN, et al. Sonographic features of hepatic adenomas with pathologic correlation. Abdom Imaging 2001;26;500–6PubMedCrossRef
48.
Zurück zum Zitat Ichikawa T, Federle MP, Grazioli L, et al. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 2000;214:861–8PubMed Ichikawa T, Federle MP, Grazioli L, et al. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 2000;214:861–8PubMed
49.
Zurück zum Zitat Katkhouda N, Hurwitz M, Gugenheim J, et al. Laparoscopic management of benign solid and cystic lesions of the liver. Ann Surg 1999;229:460–6PubMedCrossRef Katkhouda N, Hurwitz M, Gugenheim J, et al. Laparoscopic management of benign solid and cystic lesions of the liver. Ann Surg 1999;229:460–6PubMedCrossRef
50.
Zurück zum Zitat Kim J, Ahmad SA, Lowy AM, et al. An algorithm for the accurate identification of benign liver lesions. Am J Surg 2004;187:274–9PubMedCrossRef Kim J, Ahmad SA, Lowy AM, et al. An algorithm for the accurate identification of benign liver lesions. Am J Surg 2004;187:274–9PubMedCrossRef
51.
Zurück zum Zitat Kerlin P, Davis L, McGill DB, et al. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983;84(5 Pt 1):994–1002PubMed Kerlin P, Davis L, McGill DB, et al. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983;84(5 Pt 1):994–1002PubMed
52.
Zurück zum Zitat Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24:276–9PubMedCrossRef Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24:276–9PubMedCrossRef
53.
Zurück zum Zitat Mathieu D, Bruneton JN, Drouillard J, et al. Hepatic adenomas and focal nodular hyperplasia: dynamic CT study. Radiology 1986;160:53–8PubMed Mathieu D, Bruneton JN, Drouillard J, et al. Hepatic adenomas and focal nodular hyperplasia: dynamic CT study. Radiology 1986;160:53–8PubMed
54.
Zurück zum Zitat Neuberger J, Portmann B, Nunnerley HB, et al. Oral-contraceptive–associated liver tumors: occurrence of malignancy and difficulties in diagnosis. Lancet 1980;1:273–6PubMedCrossRef Neuberger J, Portmann B, Nunnerley HB, et al. Oral-contraceptive–associated liver tumors: occurrence of malignancy and difficulties in diagnosis. Lancet 1980;1:273–6PubMedCrossRef
55.
Zurück zum Zitat Paulson EK, McClellan JS, Washington K, et al. Hepatic adenoma: MR characterisitics and correlation with pathologic findings. AJR Am J Roentgenol 1994;163:113–6PubMed Paulson EK, McClellan JS, Washington K, et al. Hepatic adenoma: MR characterisitics and correlation with pathologic findings. AJR Am J Roentgenol 1994;163:113–6PubMed
56.
Zurück zum Zitat Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001;67:173–8PubMed Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001;67:173–8PubMed
57.
Zurück zum Zitat Reddy SK, Kishnani PS, Sullivan JA, et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol 2007;47:658–63PubMedCrossRef Reddy SK, Kishnani PS, Sullivan JA, et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol 2007;47:658–63PubMedCrossRef
58.
Zurück zum Zitat Toso C, Majno P, Andres A, et al. Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. World J Gastroenterol 2005;11:5691–5PubMed Toso C, Majno P, Andres A, et al. Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors. World J Gastroenterol 2005;11:5691–5PubMed
59.
Zurück zum Zitat Van der Windt DJ, Kok NFM, Hussain SM, et al. Case-orientated approach to the manaagement of hepatocellular adenoma. Br J Surg 2006;93:1495–502PubMedCrossRef Van der Windt DJ, Kok NFM, Hussain SM, et al. Case-orientated approach to the manaagement of hepatocellular adenoma. Br J Surg 2006;93:1495–502PubMedCrossRef
60.
Zurück zum Zitat Weil R 3rd, Koep LJ, Starzl T. Liver resection for hepatic adenoma. Arch Surg 1979;114:178–80PubMed Weil R 3rd, Koep LJ, Starzl T. Liver resection for hepatic adenoma. Arch Surg 1979;114:178–80PubMed
61.
Zurück zum Zitat Weimann A, Ringe B, Klempnauer J, et al. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 1997;21:983–90PubMedCrossRef Weimann A, Ringe B, Klempnauer J, et al. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 1997;21:983–90PubMedCrossRef
Metadaten
Titel
Surgical Management of Hepatocellular Adenoma: Take It or Leave It?
verfasst von
Sung W. Cho, MBBS, MSc
J. Wallis Marsh, MD
Jennifer Steel, PhD
Shane E. Holloway, MD
Jason T. Heckman, MD
Erin R. Ochoa, MD
David A. Geller, MD
T. Clark Gamblin, MD, MS
Publikationsdatum
01.10.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0090-0

Weitere Artikel der Ausgabe 10/2008

Annals of Surgical Oncology 10/2008 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.